Pharma Mar (BME:PHM) Could Be 37% Below Fair Value Following Weak Half Year Earnings

Pharma Mar (BME:PHM) is in focus after reporting first half 2026 net income of €0.561 million compared with €19.42 million a year earlier, with earnings per share from continuing operations also sharply lower.

See our latest analysis for Pharma Mar.

Pharma Mar's latest earnings update arrived after a weak patch for the stock, with a 90 day share price return down 21.21% and a 30 day share price return down 3.98%. However, the €78.4 share price still sits above levels implied by its 140.97% three year total shareholder return and 18.91% five year total shareholder return.

If Pharma Mar's recent move has you reassessing opportunities in healthcare and biotech, it could be a good moment to broaden your research and check out 129 healthcare AI stocks.

The sharp earnings drop, set against Pharma Mar’s strong multi year shareholder returns, leaves a simple tension. Does the recent setback now offer a better entry point for new buyers, or does it still skew the risk reward against them?

Most Popular Narrative: 37.3% Undervalued

At a €78.4 share price, the most followed narrative for Pharma Mar points to a fair value of €125. This gap sits on detailed forecasts for sales, margins, and cash flows that push well beyond what the recent earnings headline suggests.

The company's significant reinvestment of cash flow nearly 50% of revenues directed to R&D combined with robust grant backing, is fueling a richer late

and early-stage pipeline than peers, which could lead to multiple high-margin product launches and a step-change in long-term earnings growth as these candidates reach commercialization.

Read the complete narrative. Read the complete narrative.

Curious what kind of revenue curve and margin profile would need to sit behind a €125 fair value for Pharma Mar at a 7.47% discount rate? The narrative leans on rapid top line expansion, sharply higher profitability, and a future earnings multiple that looks very different to where the stock trades today.

Result: Fair Value of €125 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the Pharma Mar story still carries real downside risk if Zepzelca underperforms in competitive markets or if key regulatory decisions and timelines do not play out as bullish analysts expect.

Find out about the key risks to this Pharma Mar narrative.

Another View on Pharma Mar’s Valuation

The first fair value of €125 for Pharma Mar relies on detailed forecasts for revenue, margins, and cash flows. The SWS DCF model also points to an estimated future cash flow value of €418.66 per share, which suggests a very large gap versus the current €78.4 price. How comfortable are you with assumptions that far apart?

Look into how the SWS DCF model arrives at its fair value.

Next Steps

Does the mixed tone around Pharma Mar's outlook leave you unsure which way to lean? Use the full set of data, including its 4 key rewards and 1 important warning sign, to pressure test your own thesis with 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Pharma Mar?

If Pharma Mar has sharpened your focus, do not stop here. Fresh ideas often appear where you are not looking, and missing them can cost real opportunities.

• Target dependable income streams by checking out 440 dividend fortresses to help anchor your portfolio when growth stories take longer than expected.
• Hunt for quality at a sensible price with 254 high quality undervalued stocks and see which stocks currently stand out on both fundamentals and valuation.
• Strengthen your core holdings by reviewing the solid balance sheet and fundamentals stocks screener (422 results) so you are not caught off guard by fragile finances when conditions change.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com